Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Non-Current Deffered Revenue: 2023-2024

Historic Non-Current Deffered Revenue for Immunome (IMNM) over the last 1 years, with Mar 2024 value amounting to $2.2 million.

  • Immunome's Non-Current Deffered Revenue fell 76.56% to $2.2 million in Q1 2024 from the same period last year, while for Mar 2024 it was $2.2 million, marking a year-over-year decrease of 76.56%. This contributed to the annual value of $5.5 million for FY2023, which is N/A change from last year.
  • Per Immunome's latest filing, its Non-Current Deffered Revenue stood at $2.2 million for Q1 2024, which was down 59.77% from $5.5 million recorded in Q4 2023.
  • Over the past 5 years, Immunome's Non-Current Deffered Revenue peaked at $9.4 million during Q1 2023, and registered a low of $2.2 million during Q1 2024.
  • For the 2-year period, Immunome's Non-Current Deffered Revenue averaged around $5.1 million, with its median value being $5.5 million (2023).
  • Data for Immunome's Non-Current Deffered Revenue shows a maximum YoY tumbled of 76.56% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Immunome's Non-Current Deffered Revenue stood at $5.5 million in 2023, then crashed by 76.56% to $2.2 million in 2024.
  • Its last three reported values are $2.2 million in Q1 2024, $5.5 million for Q4 2023, and $2.9 million during Q3 2023.